Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease

Madilyn Coles; Genevieve Z Steiner-Lim; Tim Karl

doi:10.3389/fnins.2022.962922

Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease

Front Neurosci. 2022 Sep 2:16:962922. doi: 10.3389/fnins.2022.962922. eCollection 2022.

Authors

Madilyn Coles¹, Genevieve Z Steiner-Lim², Tim Karl^{1

3}

Affiliations

¹ School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
² NICM Health Research Institute and Translational Health Research Institute (THRI), Western Sydney University, Penrith, NSW, Australia.
³ Neuroscience Research Australia, Randwick, NSW, Australia.

Abstract

Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by declining cognition and behavioral impairment, and hallmarked by extracellular amyloid-β plaques, intracellular neurofibrillary tangles (NFT), oxidative stress, neuroinflammation, and neurodegeneration. There is currently no cure for AD and approved treatments do not halt or slow disease progression, highlighting the need for novel therapeutic strategies. Importantly, the endocannabinoid system (ECS) is affected in AD. Phytocannabinoids, including cannabidiol (CBD) and Δ⁹-tetrahydrocannabinol (THC), interact with the ECS, have anti-inflammatory, antioxidant, and neuroprotective properties, can ameliorate amyloid-β and NFT-related pathologies, and promote neurogenesis. Thus, in recent years, purified CBD and THC have been evaluated for their therapeutic potential. CBD reversed and prevented the development of cognitive deficits in AD rodent models, and low-dose THC improved cognition in aging mice. Importantly, CBD, THC, and other phytochemicals present in Cannabis sativa interact with each other in a synergistic fashion (the "entourage effect") and have greater therapeutic potential when administered together, rather than individually. Thus, treatment of AD using a multi-cannabinoid strategy (such as whole plant cannabis extracts or particular CBD:THC combinations) may be more efficacious compared to cannabinoid isolate treatment strategies. Here, we review the current evidence for the validity of using multi-cannabinoid formulations for AD therapy. We discuss that such treatment strategies appear valid for AD therapy but further investigations, particularly clinical studies, are required to determine optimal dose and ratio of cannabinoids for superior effectiveness and limiting potential side effects. Furthermore, it is pertinent that future in vivo and clinical investigations consider sex effects.

Keywords: Alzheimer’s disease; cannabidiol (CBD); cannabis extract; cannabis therapeutics; delta-9-tetrahydrocannabinol (THC); dementia; endocannabinod system.

Publication types

Review